- Home
- WRBY vs DNLI Comparison
WRBY vs DNLI Comparison
Compare WRBY & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- DNLI
- Stock Information
- Founded
- WRBY 2010
- DNLI 2013
- Country
- WRBY United States
- DNLI United States
- Employees
- WRBY N/A
- DNLI N/A
- Industry
- WRBY Ophthalmic Goods
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WRBY Health Care
- DNLI Health Care
- Exchange
- WRBY Nasdaq
- DNLI Nasdaq
- Market Cap
- WRBY 2.1B
- DNLI 2.1B
- IPO Year
- WRBY 2021
- DNLI 2017
- Fundamental
- Price
- WRBY $21.73
- DNLI $13.89
- Analyst Decision
- WRBY Buy
- DNLI Strong Buy
- Analyst Count
- WRBY 15
- DNLI 15
- Target Price
- WRBY $23.33
- DNLI $33.85
- AVG Volume (30 Days)
- WRBY 2.2M
- DNLI 1.6M
- Earning Date
- WRBY 08-07-2025
- DNLI 07-31-2025
- Dividend Yield
- WRBY N/A
- DNLI N/A
- EPS Growth
- WRBY N/A
- DNLI N/A
- EPS
- WRBY N/A
- DNLI N/A
- Revenue
- WRBY $795,094,000.00
- DNLI N/A
- Revenue This Year
- WRBY $16.13
- DNLI N/A
- Revenue Next Year
- WRBY $13.87
- DNLI $335.74
- P/E Ratio
- WRBY N/A
- DNLI N/A
- Revenue Growth
- WRBY 13.94
- DNLI N/A
- 52 Week Low
- WRBY $12.46
- DNLI $10.57
- 52 Week High
- WRBY $28.68
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- WRBY 58.96
- DNLI 45.02
- Support Level
- WRBY $21.23
- DNLI $14.19
- Resistance Level
- WRBY $22.43
- DNLI $14.88
- Average True Range (ATR)
- WRBY 0.81
- DNLI 0.77
- MACD
- WRBY -0.14
- DNLI -0.03
- Stochastic Oscillator
- WRBY 48.15
- DNLI 34.55
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.